Does AMLODIPINE Cause Product packaging quantity issue? 5 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Product packaging quantity issue have been filed in association with AMLODIPINE (Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide). This represents 0.0% of all adverse event reports for AMLODIPINE.
5
Reports of Product packaging quantity issue with AMLODIPINE
0.0%
of all AMLODIPINE reports
0
Deaths
3
Hospitalizations
How Dangerous Is Product packaging quantity issue From AMLODIPINE?
Of the 5 reports, 3 (60.0%) required hospitalization.
Is Product packaging quantity issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for AMLODIPINE. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does AMLODIPINE Cause?
Hypotension (6,504)
Toxicity to various agents (5,554)
Completed suicide (5,267)
Drug ineffective (4,091)
Dyspnoea (3,907)
Dizziness (3,536)
Intentional overdose (3,427)
Fall (3,215)
Fatigue (3,141)
Headache (2,907)
What Other Drugs Cause Product packaging quantity issue?
LEUPROLIDE (523)
ALBUTEROL (431)
BUDESONIDE\FORMOTEROL (301)
FENTANYL (286)
BUPRENORPHINE (225)
CYCLOSPORINE (206)
ESTRADIOL (201)
BIMATOPROST (177)
RIVAROXABAN (174)
EXENATIDE (154)
Which AMLODIPINE Alternatives Have Lower Product packaging quantity issue Risk?
AMLODIPINE vs AMLODIPINE BESILATE
AMLODIPINE vs AMLODIPINE\ATORVASTATIN
AMLODIPINE vs AMLODIPINE\BENAZEPRIL
AMLODIPINE vs AMLODIPINE\HYDROCHLOROTHIAZIDE\OLMESARTAN
AMLODIPINE vs AMLODIPINE\HYDROCHLOROTHIAZIDE\OLMESARTAN MEDOXOMIL